Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT00573846

Phenotypic Characteristics of Inflammatory Bowel Disease in Southeast Asian Population - A Multi-centered US Study

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
University of California, Irvine · Academic / Other
Sex
All
Age
Healthy volunteers
Accepted

Summary

This is a retrospective, case control study of inflammatory bowel disease. This study will analyze the phenotypic characteristics of inflammatory bowel disease in the Southeast Asian population and will help describe clinical characteristics and serologic profiles in Southeast Asians with inflammatory bowel disease, comparing the phenotype differences to historical Caucasian controls. The data from this study will help identify the phenotype characteristics of different ethnic groups and study the epidemiological patterns of the disease.

Detailed description

This study is a retrospective, case control study of inflammatory bowel disease characteristics in patients with origins from the Indian sub-continent. Patients will be selected from the IBD registry maintained at respective institutions. Subjects from the Indian sub-continent will be identified using their country of birth, parents' ethnicity, number of years since leaving the country of birth, and number of years residing in the United States. Using both electronic and paper databases, demographic information regarding age, gender, body mass index, smoking history, dietary habits; medical history such as type of IBD, IBD symptoms, location and behavior, medication use (past and current), history of other autoimmune disorders; surgical history (IBD and non-IBD related); laboratory indices such as IBD serology, Thiopurinemethyltransferase (TPMT), and infliximab levels will be collected. Demographics will be compared between groups using descriptive statistics. Using univariate analysis, variables that are significantly different will be identified. Conditional logistic regression will then be performed to identify those clinical variables that are statistically significant. The study duration will be one year from IRB approval.

Conditions

Timeline

Start date
2007-07-01
Primary completion
2008-10-01
Completion
2008-10-01
First posted
2007-12-14
Last updated
2015-01-28

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00573846. Inclusion in this directory is not an endorsement.